South African Tobacco Company Under Investigation for Tax Evasion

Aug.29.2022
South African Tobacco Company Under Investigation for Tax Evasion
South Africa's tax authority has imposed a restraining order on Gold Leaf Tobacco and its directors for tax evasion.

Gold Leaf Tobacco Company is one of South Africa's largest cigarette companies.


The South African Revenue Service has obtained a protective order against Gold Leaf Tobacco company and its directors Simon Rudland and Ebrahim Adamjee.


The order was approved by the High Court of the Province of North Howden, blocking tobacco manufacturers and their directors from selling any assets, while tax authorities continue to investigate tax evasion.


In a statement issued by SARS Commissioner Edward Kieswetter, he stated that the non-compliant taxpayers' actions are depriving the government of legitimate resources and harming the nation and South African public.


When dealing with this menace, SARS will continue to carry out its mission without fear, favor or prejudice.


According to a report from "The Little Cow Daily," SARS investigators have informed the court that they have evidence that Jin Ye participated in money laundering and may owe up to 3 billion rand in undeclared income tax, value-added tax, and other taxes.


The publication reported that SARS has requested the court to freeze the assets of Rudland and Adamjee as the assets of Gold Leaf alone may not be enough to repay their potential debt to SARS. Both directors deny any wrongdoing.


Founder of Tax Justice SA, Yusuf Abramjee, said that the protection order was a "significant breakthrough in the fight against the illicit cigarette trade".


He said that for more than a decade, as the illegal cigarette trade in South Africa has grown into a destructive national threat, GLTC has consistently been a primary suspect.


Statement:


This article is sourced from compiled third-party information and is meant only for industry communication and learning.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only used for industry exchange and research.


Due to limitations in the level of translation, this article may not express the original author's intent or meaning accurately. Please refer to the original article for accurate information.


2FIRSTS is fully aligning itself with the Chinese government with regards to any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


Copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
PMTA Manufacturing Panel Sees Small Firms Warn “Unknown Is Death” as FDA Defends Review Boundaries
During FDA’s Feb 10 PMTA roundtable (manufacturing controls panel), small ENDS manufacturers warned that uncertainty in manufacturing expectations creates existential financial risk. FDA officials reiterated review flexibility is constrained by statutory and scientific boundaries. The panel debated testing standards, documentation requirements, open-system responsibility, supply chain changes, and software updates—highlighting unresolved PMTA challenges for small manufacturers.
Feb.11
Bangladesh enforces a complete ban on e-cigarettes and emerging tobacco products, with jail and heavy fines
Bangladesh enforces a complete ban on e-cigarettes and emerging tobacco products, with jail and heavy fines
UNB reports that Bangladesh has imposed a complete ban on e-cigarettes, vapes, and other emerging tobacco products as the Smoking and Tobacco Products Use Control (Amendment) Ordinance, 2025 has come into effect.
Jan.04 by 2FIRSTS.ai
Five Inner West Sydney shops shut for 90 days after 780,000 illicit cigarettes and 2,200 illegal vapes seized
Five Inner West Sydney shops shut for 90 days after 780,000 illicit cigarettes and 2,200 illegal vapes seized
NSW Health has shut down five Inner West Sydney stores for 90 days after a major seizure of illicit cigarettes and illegal vapes, with two additional premises in Northern NSW also served closure notices. The action forms part of a broader crackdown that has seen 66 stores closed since new laws took effect in late 2025, with NSW Health warning further enforcement — including prosecution — may follow.
Feb.09 by 2FIRSTS.ai
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape launches Labster production unit for e-liquids and DIY concentrates
Kumulus Vape has launched Labster, a 700 sq m production unit in the Lyon Metropolis near the group’s headquarters, for e-liquids and DIY concentrates. The site is equipped with automated lines supplied by CDA (Constructions d’Automatismes) to carry out bottling and labeling. Its theoretical capacity is described as several million bottles per year in 10–100 ml formats, and it is already operational.
Feb.06 by 2FIRSTS.ai
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
The Volume Illusion: Measuring the Future of Nicotine with the Tools of the Past
As next-generation nicotine products become economically central rather than marginal, traditional volume-based metrics are increasingly unable to explain consumption, risk, and value. Units designed for a cigarette-based economy struggle to describe systems defined by delivery speed, pharmacokinetics, and adaptive user behavior. Drawing on financial reporting, regulation, and nicotine science, a fundamental question: can the future of nicotine still be measured using the tools of its past?
Feb.09 by Alan Zhao | 2Firsts Perspectives
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International: Over $20 Billion Invested in the U.S. Since 2022; IQOS ILUMA to Launch Pending FDA Authorization
Philip Morris International (PMI) said its U.S.-related investments have topped $20 billion since 2022, when it entered the U.S. market through its roughly $19 billion acquisition of Swedish Match. The company also said it plans to launch its heated tobacco product IQOS ILUMA in the United States pending authorization from the U.S. Food and Drug Administration (FDA).
Jan.16 by 2FIRSTS.ai